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Abstract
Background: Subtypes of white blood cell counts are known biomarkers of systemic inflammation and
a high neutrophil-to-lymphocyte ratio (NLR) has been associated with several autoimmune diseases.
Few studies have investigated the NLR in multiple sclerosis (MS).
Objective: To examine the association between NLR, MS and disability measured by the MS severity
score (MSSS).
Methods: Patients were included from the Danish Multiple Sclerosis Biobank. Information on patient
NLR was obtained just before their first treatment and clinical information was provided by the Danish
Multiple Sclerosis Treatment Register. Information on NLR from controls was collected from the
Danish Blood Donor Study. Patients and controls were 1:2 propensity score matched by baseline
confounders.
Results: Propensity score matching left 740 of 743 MS patients and 1420 of 4691 controls for further
analyses. Odds-ratio (OR) was 3.64 (95% confidence interval 2.87–4.60, p< 0.001) for MS disease per
unit increase of logarithmically transformed NLR (ln-NLR), corresponding to an OR of 2.68 for each
doubling of NLR. Mean NLR was 2.12 for patients and 1.72 for controls (p< 0.001). Ln-NLR correlated
weakly with patient MSSS (R2¼ 0.019, p¼ 0.008).
Conclusion: Patients with early MS had increased levels of NLR compared to healthy controls and NLR
was weakly correlated with MSSS.
Keywords: Multiple sclerosis, relapsing-remitting, systemic inflammation, neutrophil-to-lymphocyte
ratio, multiple sclerosis severity score, C-reactive protein
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune
disease in the central nervous system (CNS), where
inflammation, demyelination and axonal loss lead
to neurological symptoms and varying levels of
clinical disability.1 The aetiology is regarded as mul-
tifactorial with genetic as well as environmental
risk factors.2
Systemic inflammation might cause chronic neuro-
degeneration and is hypothesized to play an impor-
tant role in the pathogenesis of MS via production of
pro-inflammatory cytokines and the activation of
both innate and adaptive immune cells, leading to
an inflammatory response within the CNS.3,4
In the search of an easy-accessible biomarker useful
for diagnosing MS disease and predicting disease
course, several different inflammatory blood bio-
markers, e.g. tumour necrosis factor-alpha and
interleukin-6, have been investigated, but none
have proven to be clinically useful.1,5
The differential count of white blood cells is a
widely-used biomarker of systemic inflammation.
Findings of neutrophilia and lymphopenia in
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response to for example bacterial infections or
cancer, has led to the investigation of the
neutrophil-to-lymphocyte ratio (NLR) as a biomark-
er that might reflect systemic inflammation better
than the neutrophil or lymphocyte count alone.6
NLR has been linked to autoimmune diseases such
as rheumatoid arthritis7 and chronic inflammatory
bowel disease.8 An association between increased
NLR and MS was found in some previous
studies, whereas the results regarding a possible
association between MS disability and NLR are
inconsistent.4,9,10
C-reactive protein (CRP) is a more thoroughly inves-
tigated biomarker of systemic inflammation than
NLR. CRP is an acute-phase protein synthetized in
hepatocytes and released to the blood in response to
infection, inflammation and tissue injury.11
The aim of this large Danish case-control study was
to investigate whether a high NLR is associated with
MS and whether NLR is useful as a biomarker pre-
dicting MS. Furthermore, to examine if NLR or CRP
correlates with MS disability, as measured by MS
severity score (MSSS) at the start of the very first
disease modifying treatment (DMT), and to investi-
gate the association between NLR and CRP in
MS patients.
Methods
Design
The study is a retrospective case-control study com-
paring MS patients with healthy controls.
Patients
We targeted all patients from the Danish Multiple
Sclerosis Center at Copenhagen University Hospital
included in the Danish Multiple Sclerosis Biobank,
who fulfilled the McDonald criteria 2005 and
201012,13 or the Poser criteria for relapsing-
remitting MS (RRMS) and had started their very
first DMT with interferon-beta (IFN-beta) within
the period June 1996 to January 2013. Among the
about 12,500 MS cases in Denmark in 2013, 6791
had been treated with IFN-beta as their first DMT.
Of these 29.9% were enrolled in the Danish
Multiple Sclerosis Biobank.
Controls
The control group consisted of healthy Caucasian
Danish blood donors living in Greater Copenhagen,
who were recruited through the Danish Blood Donor
Study14 in the period October 2011 to May 2014
from five major blood donor locations. This recruit-
ment has been more thoroughly described
elsewhere.15
Blood tests
We obtained cell counts of neutrophils, lymphocytes
and CRP for the patients from the Department of
Clinical Biochemistry at Copenhagen University
Hospital, Rigshospitalet. We used the last blood
test values from just before commencement of
their first DMT, excluding blood tests taken within
40 days after start of short-term steroid treatment for
relapses. Counts of neutrophils and lymphocytes
from the blood donor controls were collected from
the Danish Blood Donor Study as a standard proce-
dure in connection with the bloodletting.
We only collected CRP values from the MS patients
for comparisons within this group because the
Danish Blood Donor Study used a different analytic
protocol. All CRP test results had the unit mg/l.
Clinical data
Clinical information regarding MSSS16 and date of
the commencement of first DMT as well as relapse
treatment was obtained from the Danish Multiple
Sclerosis Treatment Register.17
BMI and smoking
Information on body mass index (BMI) and smoking
came from a comprehensive questionnaire, devel-
oped at Karolinska Institute in Stockholm and with
permission translated into Danish.18 The patients
filled in the questionnaire from 2009 to 2014. The
donor controls filled in exactly the same question-
naire as the MS patients on the same day as collec-
tion of their blood sample from 2011 to 2014. BMI
was calculated by self-reported height and weight
both at 20 years of age and at the time of filling in
the questionnaire, in this paper referred to as current
BMI. For patients we chose either BMI at 20 years
of age or current BMI based on which one being
closest to the date of first DMT. For controls we
used current BMI. BMI was treated as a continuous
variable in our analyses. We dichotomized data on
smoking to a dummy variable: regular smoker or
not. BMI and smoking were not study parameters
in the present study and we only included them as
potential confounders.
Statistical methods
NLR was calculated as the quotient between the neu-
trophil and lymphocyte cell counts in blood. The
distribution of NLR was, as expected for a quotient,
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highly skewed, but after loge transformation it was
almost perfectly Gaussian distributed. We investi-
gated the association between logeNLR (ln-NLR)
and MS by binary logistic regression with MS-
case-control status as dependent variable and ln-
NLR as independent variable with adjustment for
baseline variables sex, age at blood test and smoking
(regular smoker v. not). In a complementary test, we
analysed ln-NLR as a dependent continuous variable
with MS-status as independent variable and sex, age
at blood test and smoking as covariates, using gen-
eralized linear models (GLM).
By iteration we dichotomized NLR at the specific
cut-off value resulting in peak Youdens J (sensitivi-
tyþ specificity – 1) and calculated the correspond-
ing sensitivity and specificity with 95% confidence
interval (CI).19
Data on CRP were only available for a random
subset of MS patients. Because of the distributional
properties of CRP, we dichotomized the values as
normal (<5mg/l) or elevated (5mg/l). Within the
patient group we examined the correlation between
ln-NLR and MSSS, between dichotomized CRP and
ln-NLR, and between dichotomized CRP and MSSS,
with sex, age at blood test and smoking status
as covariates.
The patients and control persons constitute two dif-
ferent populations as to distribution on sex, age and
other covariates. To make them comparable we pro-
pensity score matched individuals from the two
groups by logistic regression for variables that
would prove to be confounders, i.e. variables that
was associated with both case-control status and
NLR with p-values of less than 0.10. We used 1:2
‘nearest neighbour’ matching without replacement,
exact match for sex with exclusion of individuals
who could not be matched with individuals from
the opposite group within a ‘caliper’ of 0.2 standard
deviations of propensity score. We used SPSS v22
for data management and analyses, and for propen-
sity score matching we used a SPSS plug-in program
in the statistical software, ‘R’.20
Ethics statement
Permission to obtain clinical data from The Danish
Multiple Sclerosis Register and data on blood sam-
ples was approved by The Danish Patient Safety
Authority (3-3013-1870/1/). Written informed con-
sent regarding the questionnaire was obtained from
all MS patients and approved by the local Ethics
Committee (KF-01 314009). Informed consent
from the blood donors was obtained through the
‘The Danish Blood Donor Study’ approved by the
local Ethics Committee (M-20090237).
Results
This study included 743 MS patients and 4691
healthy blood donor controls. Patients were included
from the Danish Multiple Sclerosis Biobank consist-
ing of data on 2723 MS patients. A total of 692
patients not treated with IFN-beta, and 1288 patients
without information on NLR were not included in
this study (see Figure 1).
We propensity score matched for sex, age at blood
test and smoking status, as these background varia-
bles were associated with both NLR and case-control
status with p< 0.10 in binary logistic regression or
t-test. BMI was not a confounder as it was not asso-
ciated with ln-NLR (p¼ 0.98) and hence we did not
match or adjust for it in any analyses.
We removed three MS patients and 3271 controls by
the 1:2 matching because of unmatchable propensity
scores leaving 740 MS patients and 1420 controls for
analyses. Table 1 show the baseline variables with
and without matching.
NLR
After propensity score matching the crude mean
NLR was 2.44 in MS patients as opposed to 1.83
in controls. The crude mean ln-NLR was 0.75 in
MS patients and 0.54 in controls (see analyses
after adjustment below and in Tables 2 and 3).
Binary logistic regression analysis with ln-NLR as
independent and case/control status as dependent
variable with adjustment for sex, age and smoking,
showed highly significant effect of ln-NLR
(p< 0.0001) with an odds-ratio (OR) of 3.64 (95%
CI: 2.87–4.60) per unit increase of ln-NLR, which
Figure 1. Flowchart showing the selection of patients.
IFN: interferon; NLR: neutrophil-to-lymphocyte ratio.
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corresponds to an OR of 2.68 for each doubling of
NLR. Results from the binary logistic regression
analysis with adjustment for confounders before
and after propensity score matching are shown in
Table 2.
In the GLM analysis (Table 3) we used the opposite
design with ln-NLR as dependent variable and case-
control status as predictive variable with adjustment
for sex, age at blood test and smoking. The estimated
mean ln-NLR results and the geometric mean of
NLR with adjustment for confounders before and
after propensity score matching was 2.12 in patients
and 1.72 in controls as shown in Table 3. The dif-
ference in ln-NLR between MS and controls was
statistically significant (p< 0.0001).
NLR as predictor of MS
Figure 2 shows a receiver operating characteristic
curve (ROC) showing sensitivity by 1 minus specif-
icity of NLR relative to case-control status in the
propensity matched cases and controls. The area
under the ROC curve was 63% of the theoretical
maximum value (95% CI: 60–66). The peak value
of Youdens J (sensitivityþ specificity – 1) was 0.19
at a cutpoint of NLR of 2.07 at which the sensitivity
was 0.49 (95% CI: 0.45-0.52) and the specificity
was 0.70 (95% CI: 0.68-0.73).
NLR and MSSS
Out of the 743 patients primarily included in this
study, 713 had information on MSSS. MSSS mean
was 5.06 (95% CI: 4.87–5.26). Linear regression
was done with MSSS as dependent variable and
ln-NLR as independent variable. As sex and smok-
ing status were associated with both MSSS and
NLR, we included them as covariates in the analysis.
Ln-NLR correlated weakly with the MSSS
(R2¼ 0.019), however statistically significant
(p¼ 0.008) with regression coefficient of 0.56
(95% CI: 0.15–0.97) meaning that MSSS is
expected to increase with 0.56 for each unit increase
in ln-NLR analogous to an expected increase of 0.41
for each doubling of NLR.
Table 1. Baseline characteristics for patients and controls before and after propensity score matching.
Before propensity score matching
After propensity
score matching
MS cases Controls MS cases Controls
N¼ 743 N¼ 4691 N¼ 740 N¼ 1420
Females (%) 520 (70.0) 2149 (45.8) 517 (69.9) 974 (68.7)
Mean age at blood test (SD) 35.4 (10.0) 44.0 (12.1) 35.4 (9.9) 36.3 (10.4)
Regular smokers (%) 324 (43.6) 1598 (34.1)a 322 (43.5) 610 (43.0)
Mean BMI (SD) 24.4 (5.0)b 25.4 (3.9)c 24.4 (5.0)d 24.9 (4.0)e
SD: standard deviation.
amissing information in 30; bmissing information in 214; cmissing information in 57; dmissing information in 213;
emissing information in 15.
Table 2. Binary logistic regression of case/control status by ln-NLR with odds ratios (OR) for ln-NLR after
stepwise entering of covariates before and after propensity score matching.
Before propensity score matching
MS cases: 743; controls: 4691
After propensity score matching
MS cases: 740; controls: 1420
Adjusted for
covariates
OR per unit
ln-NLR 95% CI p
OR per unit
ln-NLR 95% CI p
None 3.40 2.80–4.12 <0.0001 3.48 2.76–4.38 <0.0001
Sex 3.27 2.68–3.99 <0.0001 3.49 2.77–4.40 <0.0001
Sexþ age 3.86 3.13–4.75 <0.0001 3.63 2.87–4.60 <0.0001
Sexþ ageþ smoking 3.89 3.16–4.80 <0.0001 3.64 2.87–4.60 <0.0001
ln-NLR: loge(neutrophil-to-lymphocyte ratio); CI: confidence interval. Bold numbers are the final results.
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CRP and NLR
In 554 of the MS patients, information on both ln-
NLR and CRP was available. We dichotomized CRP
into normal (<5mg/l) and elevated (5mg/l).
GLM adjusted for sex, age at blood test and
smoking showed that elevated CRP increases NLR.
The estimated mean ln-NLR was 0.849 with elevat-
ed CRP and 0.727 with normal CRP (p¼ 0.038)
corresponding to geometrical mean of NLR of 2.34
and 2.07, respectively.
CRP and MSSS
In 533 of the MS patients, information on both CRP
and MSSS was available. In 79 MS (14.8%) patients
the CRP was elevated. With GLM, adjusted for sex,
age at blood test and smoking, mean estimated
MSSS was 5.32 as opposed to 5.07 among those
with normal CRP. The difference was not statistical-
ly significant (p¼ 0.447).
Discussion
In this study we found that for each doubling of
NLR, the odds of MS increased 2.68 times within
the study population. Mean NLR was 2.12 for cases
and 1.72 for controls and there was a statistically
significant difference in ln-NLR between the
groups. Although the association between NLR and
MS was highly significant, NLR had, in our study,
poor value as a predictor of MS or as an ancillary
diagnostic tool, and we could not confirm the high
sensitivity and specificity in another study.4
Table 3. Mean ln-NLR in patients and controls using generalized linear models before and after propensity score matching.
Before propensity score matching
MS cases: 743; controls: 4691
After propensity score matching
MS cases: 740; controls: 1420
Adjusted for
covariates
Estimated
marginal
mean of
ln-NLRa 95% CI
Geometric
mean of
NLRb 95% CI P
Estimated
marginal
mean of
ln-NLRa 95% CI
Geometric
mean of
NLRb 95% CI P
None
Cases 0.746 0.712–0.781 2.11 2.04–2.18 <0.0001 0.748 0.713–0.782 2.11 2.04–2.19 <0.0001
Controls 0.545 0.535–0.556 1.73 1.71–1.74 0.536 0.517–0.555 1.71 1.68–1.74
Sex
Cases 0.738 0.703–0.773 2.09 2.02–2.17 <0.0001 0.747 0.712–0.782 2.11 2.04–2.18 <0.0001
Controls 0.547 0.536–0.557 1.73 1.71–1.75 0.536 0.517–0.555 1.71 1.68–1.74
Sexþ age
Cases 0.764 0.729–0.798 2.15 2.07–2.22 <0.0001 0.750 0.715–0.784 2.12 2.04–2.19 <0.0001
Controls 0.543 0.542–0.553 1.72 1.70–1.74 0.535 0.516–0.554 1.71 1.68–1.74
Sexþ ageþ smoking
Cases 0.765 0.730–0.780 2.15 2.08–2.22 <0.0001 0.750 0.715–0.784 2.12 2.05–2.19 <0.0001
Controls 0.542 0.531–0.553 1.72 1.70–1.74 0.535 0.516–0.554 1.72 1.67–1.74
aEstimated marginal means are mean values adjusted for sex, age and smoking status. bGeometric mean of NLR is the antilogarithm of the
arithmetric mean of ln-NLR.
Bold numbers are the final results.
Figure 2. Receiver operating characteristic curve showing
sensitivity and specificity of NLR in MS patients.
NLR: neutrophil-to-lymphocyte ratio; Youdens
J¼ sensitivityþ specificity – 1. The grey diagonal repre-
sents pure chance. With NLR cut-off at the peak value of
Youdens J sensitivity was 0.49 and specificity was 0.70.
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NLR correlated only weakly with MSSS, and there
was no association between CRP and MSSS despite
a statistical significant albeit weak association
between CPR and NLR.
NLR is a marker of systemic inflammation based on
routine analysis and thus with low cost and simple to
achieve. Apart from being of importance as a prog-
nostic marker in other diseases as cancer and auto-
immune diseases, small studies have indicated
importance in MS. Our study is of importance, as
our results, based on the hitherto largest number of
patients and controls, confirm findings from previ-
ous studies on NLR in MS, which all showed an
association between a high NLR and MS.4,10,21
When looking for a possible association to MS dis-
ability, the results from other studies are less consis-
tent. Two studies found NLR to correlate with
Expanded Disability Status Scale (EDSS)4,9 and
one study did not find any association.10
Giovannoni et al.22 suggest that systemic inflamma-
tion might only result in disability after several years
of MS disease, and this might explain why only a
weak association between NLR and MSSS was seen
in our patients with early MS. We chose MSSS in
preference to EDSS because it is less dependent on
disease duration. To further clarify whether NLR is
associated to MS disability, studies with long
follow-up time are needed, as this would enable
measuring of disease progression.
Tobacco smoking and high BMI are two known risk
factors for MS2 and are associated with systemic
inflammation. They have shown to be associated
with increased total white blood cell counts,
increased neutrophil counts,23,24 and with high
levels of CRP.25,26 However, in our study BMI
was neither associated with NLR or case-control
status, and hence it was not included as a covariate.
Sex, age and smoking proved to be confounders as
they were associated with both case-control status
and NLR in our study. To make our patient and
control group comparable, patients and controls
were propensity score matched for these variables.
Removal of unmatchable individuals from both
groups resulted in a better balance between the
groups as to the known confounders. When looking
at the results of the binary logistic regression analy-
sis before propensity score matching, sex appeared
to be a positive confounder, whereas age and smok-
ing were negative confounders. Our results showed a
highly significant effect of NLR both before and
after propensity score matching, with only a slight
decrease in OR after matching. The difference
between the estimated marginal means of ln-NLR
between patients and controls was also highly statis-
tically significant both before and after propensity
score matching (p< 0.001).
NLR has been linked to different autoimmune dis-
eases7,8 and neurological diseases including
Alzheimer’s disease27 and Parkinson’s disease.28
NLR has been shown to be correlated to the prog-
nosis of diseases such as rheumatoid arthritis,7
cancer29 and stroke.30
Neutrophil count appears to be increased in MS
patients with an elevation of NLR compared to
healthy controls.10,31 The cause of this increase
and whether increased neutrophil counts contribute
to the development of CNS autoimmunity
remains unclear.32
Studies on experimental autoimmune encephalomy-
elitis (EAE), the animal model of MS, showed that
depletion of neutrophils led to a reduction in the
development of the disease, and that neutrophils
might play an important role in the pathogenesis of
EAE by producing cytokines, impairing the blood
brain barrier, and by contributing to parenchymal
brain inflammation.32 Naegele et al.31 demonstrated
that the increase in neutrophil count in RRMS is
most likely due to a decrease in apoptosis and that
neutrophils had an altered expression of surface mol-
ecules, which might enhance recruitment to sites of
inflammation. They also found that neutrophils had
enhanced effector mechanisms, including degranula-
tion, oxidative burst and release of neutrophil extra-
cellular traps, which might cause tissue injury and
demyelination, enhance T-cell activation and impair
the blood brain barrier, thereby contributing to MS
pathogenesis.31 Neutrophils are, however, not part of
the cellular infiltrate in MS.
Only a subgroup of the patients in our study had
information on CRP. Elevated levels of CRP are
associated with different autoimmune diseases,11
and other studies have examined CRP and its asso-
ciation with MS disability, but the results are incon-
clusive.4,9,22,33 Our study showed a weak association
between increased CRP levels and the NLR but no
association between CRP and MSSS.
The strengths of our study are the large sample size
as well as the fact that patients were treatment naı¨ve,
since we sampled blood tests before their first dose
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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of DMT ever. Steroid treatment affects white blood
cell counts, but the increase in neutrophil count, and
thereby NLR, disappears before 48 hours after discon-
tinuation of prednisolone,34 and by ignoring blood
tests closer to steroid treatment than 40 days, it is
unlikely that our results are affected by medication
taken in relation to MS.
Limitations of this study are the lack of information
about medications, apart from steroids and DMT,
and lack of information about other diseases or
infections that might contribute to an elevation in
systemic inflammatory markers in MS patients.
Another limitation is the inclusion of solely RRMS
patients and thus no evaluation of other MS forms.
Furthermore the use of blood donors as control
group can be considered a limitation, as blood
donors constitute a healthy subset of the general
population with better than average health, probably
due to the strict selection criteria.35 Also the fact that
blood donation is not allowed during infections
might reduce systemic inflammation in blood
donors compared to the general population and
might contribute to the difference in NLR seen
between our patients and controls.
Conclusions
We found that patients with early MS, just before
their first DMT, had increased systemic inflamma-
tion, as measured by NLR, compared to controls,
and that NLR was weakly correlated with MSSS.
To further clarify the association between NLR
and MS disease and disability, more studies prefer-
ably of large size and with long follow up time are
needed. The results from our and other studies sug-
gest that an elevated NLR is associated with MS, and
therefore investigating the role of neutrophils in MS
patients might provide new insights into the patho-
genesis of MS.
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